CNBX
CNBX Pharmaceuticals Inc.
Key Financials
Gross Profit
$5684
↓ 94.9%
Revenue
$0
↓ 100.0%
Net Income
$-313976
↑ 54.8%
Operating Income
$-271691
↑ 53.4%
EPS (Diluted)
$0.00
↑ 100.0%
Total Liabilities
$491164.00
↑ 45.2%
Shareholders' Equity
$-2496293.00
↓ 0.7%
Cash & Equivalents
$15111.00
↓ 42.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/1/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 6/24/2026 | View on SEC |
| SCHEDULE 13G/A | 5/8/2026 | View on SEC |
| 10-Q | 4/14/2026 | View on SEC |
| 8-K | 3/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/5/2026 | View on SEC |
| 10-Q | 1/14/2026 | View on SEC |
| 10-K | 12/1/2025 | View on SEC |
| SCHEDULE 13G/A | 11/10/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CNBX |
| Company Name | CNBX Pharmaceuticals Inc. |
| CIK | 1343009 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0831 |
| State of Incorporation | NV |
| Phone | 877-424-2429 |